In vivo screen identifies LXR agonism potentiates sorafenib killing of hepatocellular carcinoma
M. E. Preziosi, A. M. Zahm, A. Vasquez-Salgado, D. Ackerman, T. Gade, K. H. Kaestner, K. J. Wangensteen
The paper identifies LXR agonism as a potential enhancer of sorafenib's efficacy in treating hepatocellular carcinoma through an in vivo genetic screen and mechanistic studies.
bioRxiv · Jun 13, 2019 · PreprintCancer Biology